The Lancet Oncology· Guang-Yi Sun, Si-Ye Chen, Yu Tang, Hui Fang, Yong-Wen Song, Yue-Ping Liu, Jing Jin, Ning Li, Ning-Ning Lu, Yuan Tang, Shu-Nan Qi, Bo Chen, Hao Jing, Yi-Rui Zhai, Wen-Wen Zhang, Xin Liu, Zhuan-Bo Yang, Xu-Ran Zhao, Yu-Chun Song, Dan-Qiong Wang, Shi-Jia Wang, Zi-Han Qiu, Chao-Nan Zhang, Shi-Jie Yang, Jing-Ru Zhu, Jia-Rong Liu, Xu-Wen Shen, Chen Hu, Ye-Xiong Li, Shu-Lian Wang·· 2026-10-01AI 评分60
高危及乳腺癌患者术后放疗:CHN HYPOPMRT III期随机非劣效试验10年随访结果
[Articles] Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial
AI 导读
CHN HYPOPMRT随机非劣效III期试验显示,与大分割程放疗相比,低分割程放疗在实现持久局部区域控制的同时,未增加严重晚期不良事件,支持其作为更节省时间的替代方案。
来源:The Lancet Oncology · thelancet.com